This protocol addresses low-grade B-cell primary pulmonary lymphoma of MALT type presenting as a localised pulmonary tumour, in the absence of bilateral or extrapulmonary involvement.
Low-grade pulmonary B-cell lymphoma is the most frequent form of primary pulmonary clonal lymphoid proliferation. It arises from mucosa-associated lymphoid tissue. For localised tumours, surgical resection is commonly preferred; the protocol below outlines the systemic treatment approach for cases managed without surgery.
Systemic treatment for this presentation centres on exclusive single-agent chemotherapy. Evidence shows that single-agent regimens are as effective as combination approaches — the specific agent selection and full treatment algorithm are detailed in the structured regimen.
DOI: 10.1183/09031936.02.00404102
Low-grade pulmonary B-cell lymphoma is the most frequent form of primary pulmonary clonal lymphoid proliferation. It arises from mucosa-associated lymphoid tissue. Nevertheless, surgical resection is commonly preferred for localised tumours.
Exclusive chemotherapy is generally used for patients with bilateral or extrapulmonary involvement, relapse or progression. Combination regimens, such as cyclophosphamide, adriamycin, oncovin and prednisone (CHOP), have not proven more effective than single-agent regimens with chloraminophene, cyclophosphamide, azathioprine or steroids.
View source ↗